个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Chang, Xiang[1] * ; Rong, Cuiping[1] * ; Chen, Yunbo[1,2] * ; Yang, Cong[1] ; Hu, Qian[3] ; Mo, Yousheng[1] ; Zhang, Chunxia[1] ; Gu, Xiaoqiong[4] ; Zhang, Lei[1] ; He, Wenqing[1] ; Cheng, Shuyi[1,2] ; Hou, Xueqin[1] ; Su, Ruyu[1] ; Liu, Sijun[1] ; Dun, Wenjun[1] ; Wang, Qi[1,2,*1] ; Fang, Shuhuan[1,2,*1] ;
机构： [1]PDME Center, Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China [2]Department of Encephalopathy, The Second Affliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510080, Guangdong Province, China [3]Department of Oncology, Sun Yat Sen Memorial Hospital of Sun Yat- Sen University, Guangzhou 510120, Guangdong Province, China [4]Guangzhou Women and Children's Medical Center, Guangzhou 510623, China
出处：
DOI： 10.1016/j.yexcr.2015.04.004
ISSN：

关键词： (-)-Epigallocatechin-3-gallate Alzheimer's disease beta-Amyloid Neprilysin Histone deacetylase inhibitor

摘要：
Epigenetic changes are involved in learning and memory, and histone deacetylase (HDAC) inhibitors are considered potential therapeutic agents for Alzheimer's disease (AD). We previously reported that (-)-epigallocatechin-3-gallate (EGCG) acts as an HDAC inhibitor. Here, we demonstrate that EGCG reduced beta-amyloid (A beta) accumulation in vitro and rescued cognitive deterioration in senescence-accelerated mice P8 (SAMP8) via intragastric administration of low- and high-dose EGCG (5 and 15 mg/kg, respectively) for 60 days. The AD brain has decreased levels of the rate-limiting degradation enzyme of A beta, neprilysin (NEP). We found an association between EGCG-induced reduction in A beta accumulation and elevated NEP expression. Further, NEP silencing prevented the EGCG-induced A beta downregulation. Our findings suggest that EGCG might be effective for treating AD. (C) 2015 Elsevier Inc. All rights reserved.

基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81403144, 81273817, 81473740]; Program for Doctoral Station in University, China [20114425110007, 20124425120016, 20134425110003]; Major Science and Technology Projects of Guangdong Province, China [2012A080202017]; Guangdong Provincial Department of Science and Technology Foundation, China [2010A030100009]; Guangdong Natural Science Fund, China [S2012040006514, S2013010012520]; Scientific and Technical Innovation Project of Guangdong Provincial Education Department of China [2012KJCX0032]; Guangdong Province Medical Research Foundation [B2012151]; South China Chinese Medicine Collaborative Innovation Center [A1-AFD01514A05]; Characteristic Key Discipline Construction Fund of Chinese Internal Medicine of Guangzhou University of Chinese Medicine
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学 4 区 细胞生物学
最新[2025]版：
大类 | 3 区 生物学
小类 | 4 区 细胞生物学 4 区 肿瘤学
JCR分区：
出版当年[2013]版：
Q2 CELL BIOLOGY Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY Q3 CELL BIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者：
第一作者机构： [1]PDME Center, Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
共同第一作者：
通讯作者：
通讯机构： [1]PDME Center, Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China [2]Department of Encephalopathy, The Second Affliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510080, Guangdong Province, China [*1]DME Center, Clinical Pharmacology Institute, Guangzhou University of Chinese Medicine, 12 Jichang Road, Guangzhou 510080, China
推荐引用方式(GB/T 7714)：
Chang Xiang,Rong Cuiping,Chen Yunbo,et al.(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression[J].EXPERIMENTAL CELL RESEARCH.2015,334(1):136-145.doi:10.1016/j.yexcr.2015.04.004.
APA：
Chang, Xiang,Rong, Cuiping,Chen, Yunbo,Yang, Cong,Hu, Qian...&Fang, Shuhuan.(2015).(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.EXPERIMENTAL CELL RESEARCH,334,(1)
MLA：
Chang, Xiang,et al."(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression".EXPERIMENTAL CELL RESEARCH 334..1(2015):136-145

相关文献

[1]Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma [2]表没食子儿茶素没食子酸酯对D-半乳糖诱导的AD模型小鼠Aβ生成作用的研究 [3](-)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein [4]A novel role of HuR in -Epigallocatechin-3-gallate (EGCG) induces tumour cells apoptosis. [5]β-asarone modulates Beclin-1, LC3 and p62 expression to attenuate Aβ40 and Aβ42 levels in APP/PS1 transgenic mice with Alzheimer's disease [6]Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer's disease mouse model and proteomics analysis [7]Protective role of phenylethanoid glycosides, Torenoside B and Savatiside A, in Alzheimer's disease. [8]Licochalcone B, a chalcone derivative from Glycyrrhiza inflata, as a multifunctional agent for the treatment of Alzheimer's disease [9]Targeted brain delivery of RVG29-modified rifampicin-loaded nanoparticles for Alzheimer's disease treatment and diagnosis [10]Fish oil protects the blood-brain barrier integrity in a mouse model of Alzheimer's disease.

资源点击量：2020 今日访问量：0 总访问量：646 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号